Neuphoria Therapeutics Faces Delisting Concerns

TL;DR

Neuphoria's on the chopping block - might get delisted!

AI Summary

Neuphoria Therapeutics Inc. filed an 8-K on September 16, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule. The filing indicates potential issues with the company's continued listing on the stock exchange, with the earliest event reported on September 10, 2025. The company is incorporated in Delaware and its principal executive offices are located in Burlington, Massachusetts.

Why It Matters

This filing signals potential financial distress or non-compliance with exchange rules, which could significantly impact the stock's liquidity and investor confidence.

Risk Assessment

Risk Level: high — A notice of delisting directly threatens the company's ability to remain publicly traded, posing a significant risk to investors.

Key Players & Entities

• Neuphoria Therapeutics Inc. (company) — Registrant
• September 10, 2025 (date) — Earliest event reported
• September 16, 2025 (date) — Date of report
• Delaware (jurisdiction) — State of incorporation
• Burlington, Massachusetts (location) — Principal executive offices
• 001-41157 (identifier) — Commission File Number

FAQ

Key Financial Figures

• $0.00001 — nge on which registered Common Stock, $0.00001 par value per share NEUP The Nasdaq

Filing Documents

• ea0257502-8k_neuphoria.htm (8-K) — 28KB
• 0001213900-25-087950.txt ( ) — 189KB
• neup-20250910.xsd (EX-101.SCH) — 3KB
• neup-20250910_lab.xml (EX-101.LAB) — 33KB
• neup-20250910_pre.xml (EX-101.PRE) — 22KB
• ea0257502-8k_neuphoria_htm.xml (XML) — 3KB

01. Notice

Item 3.01. Notice of Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. As previously disclosed on July 18, 2025, Neuphoria Therapeutics Inc. (the "Company") received a deficiency notification letter (the " Notice ") from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (" Nasdaq "). The Notice indicated that the Company was not in compliance with Nasdaq Listing Rule 5620(a) (the " Listing Rule ") as a result of the Company's failure to hold an annual general meeting of stockholders within twelve months of the end of the Company's fiscal year ended June 30, 2024. The Listing Rule requires that a Nasdaq-listed company hold an annual meeting of shareholders no later than one year after the end of the company's fiscal year end. Pursuant to and in response to that Notice, the Company timely submitted its plan to Nasdaq to regain compliance with the Listing Rule (the " Plan "). In response to the Company's Plan, on September 10, 2025, Nasdaq provided the Company further notice that is has accepted our Plan and granted the Company an extension of 180 calendar days (the " Compliance Period ") from the end of the Company's fiscal year, or until December 29, 2025, to regain compliance with the Listing Rule. To this end, the Company intends to file its annual report on Form 10-K on or before September 29, 2025, and thereafter, the Company intends to timely file a proxy to hold such annual shareholder meeting within the Compliance Period.

Forward-Looking Statements

Forward-Looking Statements This Current Report on Form 8-K includes forward-looking statements that involve risks and uncertainties. Forward-looking statements are statements that are not historical facts. Such forward-looking statements are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements. These forward-looking statements and factors that may cause such differences include, without limitation, the ability of the Company to maintain the listing of its securities on Nasdaq and the risks and uncertainties indicated from time to time in the Company's filings with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. The Company expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company's expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.

01 Financial Statements

Item 9.01 Financial Statements and Exhibits. Exhibit No. Description 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 1

SIGNATUREs

SIGNATUREs Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. NEUPHORIA THERAPEUTICS INC. By: /s/ Spyridon Papapetropoulos Spyridon Papapetropoulos Chief Executive Officer Date: September 16, 2025 2

View Full Filing

View this 8-K filing on SEC EDGAR